Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: A population-based analysis

M.P.P. van Herk-Sukel, L.V. van de Poll-Franse, A.C. Voogd, G.A.P. Nieuwenhuijzen, J.W.W. Coebergh, R.M.C. Herings

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
Pages (from-to)843-851
JournalBreast Cancer Research and Treatment
Volume122
Issue number3
Publication statusPublished - 2010

Cite this

@article{a7e8a1492356441aaedf6af7239261ee,
title = "Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: A population-based analysis",
author = "{van Herk-Sukel}, M.P.P. and {van de Poll-Franse}, L.V. and A.C. Voogd and G.A.P. Nieuwenhuijzen and J.W.W. Coebergh and R.M.C. Herings",
year = "2010",
language = "English",
volume = "122",
pages = "843--851",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years : A population-based analysis. / van Herk-Sukel, M.P.P.; van de Poll-Franse, L.V.; Voogd, A.C.; Nieuwenhuijzen, G.A.P.; Coebergh, J.W.W.; Herings, R.M.C.

In: Breast Cancer Research and Treatment, Vol. 122, No. 3, 2010, p. 843-851.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years

T2 - A population-based analysis

AU - van Herk-Sukel, M.P.P.

AU - van de Poll-Franse, L.V.

AU - Voogd, A.C.

AU - Nieuwenhuijzen, G.A.P.

AU - Coebergh, J.W.W.

AU - Herings, R.M.C.

PY - 2010

Y1 - 2010

M3 - Article

VL - 122

SP - 843

EP - 851

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -